MarketPulse

diabetes

5 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Novo Nordisk Bets on OpenAI Partnership to Reshape Drug Development Economics

Novo Nordisk partners with OpenAI to accelerate drug discovery via AI. Long-term benefits possible, but near-term headwinds from competition and clinical setbacks persist.
LLYNVOclinical trialsdiabetes
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Nxera Pharma Hits Second Eli Lilly Milestone in Metabolic Disease Push

Nxera Pharma achieves second milestone with Eli Lilly validating its GPCR-targeting platform. Deal includes $694M in potential payments plus royalties.
LLYdiabetesdrug discovery
GlobeNewswire Inc.GlobeNewswire Inc.··Feature Impact

Heart Disease's Hidden Allies: AHA Tackles Interconnected Health Epidemic

American Heart Association launches Cardiovascular-Kidney-Metabolic initiative to address interconnected diseases affecting 90% of U.S. adults, emphasizing screening and prevention.
NVSNVOBAYRYDVAkidney diseasediabetes
BenzingaBenzinga··Vandana Singh

Embecta Expands Drug-Delivery Portfolio With $200M Owen Mumford Acquisition

Embecta to acquire UK firm Owen Mumford for up to $200M, bolstering drug-delivery capabilities and chronic care market reach. Stock rises 4.63%.
EMBCacquisitionM&A
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Novo Nordisk Licenses Vivtex Technology for Oral Obesity and Diabetes Treatments

Novo Nordisk licenses Vivtex's oral drug-delivery technology for obesity and diabetes treatments, with potential $2.1B in milestone payments to develop oral alternatives to injectable biologics.
NVOpartnershipobesity treatment